Denosumab for treatment of postmenopausal osteoporosis
- MAGIC BULLETS WITH A HEFTY PRICE TAG. Shaughnessy, Allen // BMJ: British Medical Journal;12/15/2012, Vol. 345 Issue 7887, p18
The article discusses the sale and use of monoclonal antibodies such as Alemtuzumab and Natalizumab and their marketing by drug manufacturing companies. It explains the use of monoclonal antibodies for treatment and the evidence supporting it. It states the reason for expensiveness of monoclonal...
- Osteoporosis Injection Shows Long-Term Efficacy in Increasing Bone Mineral Density. // Journal of Gerontological Nursing;Jul2011, Vol. 37 Issue 7, p16
The article focuses on long-term data concerning treatment with denosumab into the fourth and fifth year by postmenopausal women with osteoporosis. It states that there were statistically significant, year-over-year increases in total hip and lumbar spine bone mineral density. It mentions that...
- Denosumab: A Review of its Use in Postmenopausal Women with Osteoporosis. Scott, Lesley // Drugs & Aging;Jul2014, Vol. 31 Issue 7, p555
Subcutaneous denosumab (Prolia [USA, Europe]; Pralia [Japan]) once every 6 months is indicated in several countries for the treatment of postmenopausal women with osteoporosis at increased or high risk for fractures (featured indication). In some countries, it is also indicated for use in...
- Novel treatment for UC at a discount. // Gastrointestinal Nursing;Apr2015, Vol. 13 Issue 3, p12
The article reports that the National Institute for Health and Care Excellence has placed a condition on the use of Entyvio for the treatment of ulcerative colitis for manufacturers to offer a discount.
- Osteoporosis treatment options expand. // Mayo Clinic Health Letter;Nov2010, Vol. 28 Issue 11, p4
The article offers information on Denosumab (Prolia), a twice-yearly injectable drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of osteoporosis.
- Breast Cancer Drug Appears to Extend Patients' Lives by 15 Months. MCBRIDE, DEBORAH // ONS Connect;Dec2014, Vol. 29 Issue 4, p35
The article discusses research which investigated the effectiveness of monoclonal antibody pertuzumab in improving survival of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Topics explored include the combination of pertuzumab and trastuzumab in blocking...
- Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Hadji, P.; Papaioannou, N.; Gielen, E.; Feudjo Tepie, M.; Zhang, E.; Frieling, I.; Geusens, P.; Makras, P.; Resch, H.; Möller, G.; Kalouche-Khalil, L.; Fahrleitner-Pammer, A. // Osteoporosis International;Oct2015, Vol. 26 Issue 10, p2479
Summary: Persistence with and adherence to osteoporosis therapy are critical for fracture reduction. This non-interventional study is evaluating medication-taking behavior of women with postmenopausal osteoporosis (PMO) receiving denosumab in Germany, Austria, Greece, and Belgium. Patients were...
- Implications and benefits of the NICE appraisal of pembrolizumab. Danson, Sarah // British Journal of Healthcare Management;Nov2015, Vol. 21 Issue 11, p506
No abstract available.
- Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Silverman, S.; Siris, E.; Kendler, D.; Belazi, D.; Brown, J.; Gold, D.; Lewiecki, E.; Papaioannou, A.; Simonelli, C.; Ferreira, I.; Balasubramanian, A.; Dakin, P.; Ho, P.; Siddhanti, S.; Stolshek, B.; Recknor, C. // Osteoporosis International;Jan2015, Vol. 26 Issue 1, p361
Summary: To determine persistence with subcutaneous denosumab every 6 months in women being treated for osteoporosis, we conducted a single-arm prospective, observational study in the United States and Canada. Among 935 patients enrolled, 12-month persistence was 82 %, with 66 patients (7 %)...